Role of urokinase receptor in tumor progression and development

Theranostics

Volumn 3, Issue 7, 2013, Pages 487-495

  Noh, Hyangsoon ^a   Hong, Sungguan ^a   Huang, Shuang ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

uPA; uPAR; Urokinase receptor

Indexed keywords

TUMOR MARKER; UROKINASE RECEPTOR; VITRONECTIN;

3' UNTRANSLATED REGION; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL MIGRATION; DISEASE MARKER; DOWN REGULATION; ENDOCYTOSIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTENSION GENE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; METASTASIS; NONHUMAN; ONCOGENE; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; STOMACH CANCER; TUMOR CELL; TUMOR INVASION; UPAR GENE; UPREGULATION;

EID: 84883178224     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4218     Document Type: Review

References (115)

1. Nguyen DX, Bos PD, and Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9:274-284.
2. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des. 2004; 10:39-49.
3. Choong PF, and Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res. 2003;:S46-58.
4. Tyndall JD, Kelso MJ, Clingan P, and Ranson M. Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. Recent Pat Anticancer Drug Discov. 2008; 3:1-13.
5. Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, Wurtz SO, Brunner N, and Gold MA. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008; 111:89-94.
6. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, and Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991; 266:1926-1933.
7. Ploug M, and Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. FEBS Lett. 1994; 349:163-168.
8. Blasi F, and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol . 2002; 3:932-943.
9. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, and Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-32388.
10. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, Shaw DE, Furie B, Furie BC, and Huang M. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 2008;15:422-423.
11. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999; 82:298-304.
12. Tjwa M, Sidenius N, Moura R, Jansen S, Theunissen K, Andolfo A, De Mol M, Dewerchin M, Moons L, Blasi F, Verfaillie C, and Carmeliet P. Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. The Journal of clinical investigation. 2009; 119:1008-1018.
13. Andolfo A, English WR, Resnati M, Murphy G, Blasi F, and Sidenius N. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost. 2002; 88:298-306.
14. Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F, et al. ligand-free A, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. The Journal of clinical investigation . 1993; 92:2160-2167.
15. Lau HK, and Kim M. Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul Fibrinolysis. 1994; 5:473-478.
16. Wahlberg K, Hoyer-Hansen G, and Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 1998; 58:3294-3298.
17. Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, and Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998; 58:1843-1849.
18. Rasch MG, Lund IK, Almasi CE, and Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci. 2008; 13:6752-6762.
19. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, and Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992; 267:18224-18229.
20. Blasi F, and Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010; 584:1923-1930.
21. Floridon C, Nielsen O, Holund B, Sunde L, Westergaard JG, Thomsen SG, and Teisner B. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. Placenta. 1999; 20:711-721.
22. Uszynski M, Perlik M, Uszynski W, and Zekanowska E. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications. Eur J Obstet Gynecol Reprod Biol. 2004; 114:54-58.
23. Solberg H, Ploug M, Hoyer-Hansen G, Nielsen BS, and Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem. 2001; 49:237-246.
24. Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, Hansen NE, and Dano K. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 1994; 102:835-841.
25. Nykjaer A, Moller B, Todd RF, Christensen T, Andreasen PA, Gliemann J, and Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994; 152:505-516.
26. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, and Reiser J. Modification of kidney barrier function by the urokinase receptor. Nature medicine. 2008; 14:55-63.
27. Beschorner R, Schluesener HJ, Nguyen TD, et al. Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and in humans FCI. Neuropathol Appl Neurobiol. 2000; 26:522-527.
28. Smith HW, and Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010; 11:23-36.
29. Alpizar-Alpizar W, Nielsen BS, Sierra R, Illemann M, Ramirez JA, Arias A, Duran S, Skarstein A, Ovrebo K, Lund LR, and Laerum OD. Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. Int J Cancer. 2010; 126:405-415.
30. Nielsen BS, Rank F, Illemann M, Lund LR, and Dano K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer. 2007; 120:2086-2095.
31. Ulisse S, Baldini E, Sorrenti S, and D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Current cancer drug targets. 2009; 9:32-71.
32. Kita Y, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, and Mori M. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer 2009; 100:153-159.
33. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N, and Harris AL. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8:1132-1141.
34. Pacheco MM, Nishimoto IN, Mourao NM, Mantovani EB, and Brentani MM. Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers 2001;16:62-68.
35. de Witte JH, Foekens JA, Brunner N, Heuvel JJ, van Tienoven T, Look MP, Klijn JG, Geurts-Moespot A, Grebenchtchikov N, Benraad T, and Sweep CG. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer 2001; 85:85-92.
36. Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli C, Keramopoulos A, and Nakopoulou L. The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett 2007;246:262-267.
37. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, and Allgayer H. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer. 2006; 106:1026-1035.
38. Alpizar-Alpizar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, and Laerum OD. Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. Int J Cancer. 2012;131(4):E329-36.
39. de Bock CE, and Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004; 24:13-39.
40. Montuori N, Visconte V, Rossi G, and Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost. 2005; 93:192-198.
41. Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G, Blasi F, Talamini G, Bassi C, and Scarpa A. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC cancer. 2011; 11:448.
42. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, and Brunner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem. 1997; 43:1868-1876.
43. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, Pfarr CM, and Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem. 1996; 271:23176-23184.
44. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, and Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res. 2005; 11:8538-8548.
45. Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, and Allgayer H. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res. 2007; 13:1123-1132.
46. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, and Semenza GL. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63:1138-1143.
47. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, and Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453:807-811.
48. Shetty S. Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells. Mol Cell Biochem. 2005; 272:107-118.
49. Tran H, Maurer F, and Nagamine Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol Cell Biol. 2003; 23:7177-7188.
50. Shetty S, Velusamy T, Idell S, Shetty P, Mazar AP, Bhandary YP, and Shetty RS. Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. Mol Cell Biol. 2007; 27:5607-5618.
51. Sasayama T, Nishihara M, Kondoh T, Hosoda K, and Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer. 2009; 125:1407-1413.
52. Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J, Wang X, You Y, Yang Z, and Liu N. MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res. 2011; 1389:9-18.
53. Ellis V, Pyke C, Eriksen J, Solberg H, and Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann N Y Acad Sci. 1992; 667:13-31.
54. Fisher JL, Mackie PS, Howard ML, Zhou H, and Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res. 2001; 7:1654-1660.
55. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, and Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry. 1982; 21:6410-6415.
56. Ellis V, Behrendt N, and Dano K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem . 1991; 266:12752-12758.
57. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, and Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science (New York). 2006; 311:656-659.
58. Czekay RP, and Loskutoff DJ. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol . 2009; 220:655-663.
59. Cubellis MV, Wun TC, and Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990; 9:1079-1085.
60. Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, and Blasi F. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol . 1995; 131:1609-1622.
61. Czekay RP, Kuemmel TA, Orlando RA, and Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Molecular biology of the cell. 2001; 12:1467-1479.
62. Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992; 267:14543-14546.
63. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, and Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO. 1997; 16:2610-2620.
64. Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, Roigaard H, Min HY, Vilhardt F, Moller LB, Kornfeld S, and Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol. 1998; 141:815-828.
65. Isacke CM, van der Geer P, Hunter T, and Trowbridge IS. p180, a novel recycling transmembrane glycoprotein with restricted cell type expression. Mol Cell Biol. 1990; 10:2606-2618
66. Howard MJ, and Isacke CM. The C-type lectin receptor Endo180 displays internalization and recycling properties distinct from other members of the mannose receptor family. J Biol Chem. 2002; 277:32320-32331.
67. Engelholm LH, Nielsen BS, Dano K, and Behrendt N. The urokinase receptor associated protein (uPARAP/endo180): a novel internalization receptor connected to the plasminogen activation system. Trends Cardiovasc Med. 2001; 11:7-13.
68. Cortese K, Sahores M, Madsen CD, Tacchetti C, and Blasi F. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS ONE. 2008; 3:3730.
69. Ma Z, Thomas KS, Webb DJ, Moravec R, Salicioni AM, Mars WM, and Gonias SL. Regulation of Rac1 activation by the low density lipoprotein receptor-related protein. J Cell Biol. 2002; 159:1061-1070.
70. Webb DJ, Nguyen DH, and Gonias SL. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci. 2000; 113:123-134.
71. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, and Rao JS. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. International journal of oncology. 2007; 31:19-27.
72. Wang Z, Li Y, Banerjee S, and Sarkar FH. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res . 2008; 28:3621-3630.
73. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, and Pieper RO. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007; 106:417-427.
74. Raghu H, Gondi CS, Dinh DH, Gujrati M, and Rao JS. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor. Mol Cancer. 2011; 10:130.
75. Nusrat AR, and Chapman HA. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. The Journal of clinical investigation. 1991; 87:1091-1097.
76. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, and Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem . 2009; 284:22825-22833.
77. Lester RD, Jo M, Montel V, Takimoto S, and Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 2007; 178:425-436.
78. Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, and Gonias SL. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res 2010;70:8948-8958.
79. Waltz DA, and Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem. 2010; 269:14746-14750.
80. Sidenius N, Sier CF, and Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000; 475:52-56.
81. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, and Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO. 2005; 24:1655-1663.
82. Deng G, Curriden SA, Hu G, Czekay RP, and Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol. 2001; 189:23-33
83. Sidenius N, and Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer metastasis reviews. 2003; 22:205-222.
84. De Bock CE, Lin Z, Mekkawy AH, Byrne JA, and Wang Y. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International journal of oncology. 2010; 36:1155-1163.
85. Wei Y, Yang X, Liu Q, Wilkins JA, and Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999; 144:1285-1294.
86. Bass R, Werner F, Odintsova E, Sugiura T, Berditchevski F, and Ellis V. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem. 2005; 280:14811-14818.
87. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, and Stockinger H. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. The Journal of experimental medicine. 1995; 181:1381-1390.
88. Xue W, Kindzelskii AL, Todd RF, and Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol. 1994; 152:4630-4640.
89. Sitrin RG, Todd RF, Albrecht E, and Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. The Journal of clinical investigation 1996; 97:1942-1951.
90. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, and Chapman HA. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood. 1996; 88:3185-3194.
91. Gyetko MR, Sitrin RG, Fuller JA, Todd RF, Petty H, and Standiford TJ. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leukoc Biol. 1995; 58:533-538.
92. Aguirre GJA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002; 21:2513-2524.
93. Liu D, Aguirre Ghiso J, Estrada Y, and Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer cell. 2002; 1:445-457.
94. Zhang F, Tom CC, Kugler MC, Ching TT, Kreidberg JA, Wei Y, and Chapman HA. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J Cell Biol . 2003;163:177-188.
95. Tang CH, Hill ML, Brumwell AN, Chapman HA, and Wei Y. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins. J Cell Sci. 2008; 121:3747-3756.
96. Jo M, Thomas KS, O'Donnell DM, and Gonias SL. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor. J Biol Chem.2003; 278:1642-1646.
97. Wei Y, Tang CH, Kim Y, Robillard L, Zhang F, Kugler MC, and Chapman HA. Urokinase receptors are required for alpha 5 beta 1 integrin-mediated signaling in tumor cells. J Biol Chem. 2007; 282:3929-3939.
98. Ossowski L, and Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Current opinion in cell biology. 2000; 12:613-620
99. Yu W, Kim J, and Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol. 1997; 137:767-777.
100. Aguirre GJA, Kovalski K, and Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and signaling MAPK. J Cell Biol. 1999; 147:89-104.
101. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, and Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci US. 2002; 99:1359-1364.
102. Loridon-Rosa B, Vielh P, Cuadrado C, and Burtin P. Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am J Clin Pathol. 1988; 90:7-16.
103. Smith HW, Marra P, and Marshall CJ. uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J Cell Biol . 2008; 182:777-790.
104. Degryse B, Resnati M, Czekay RP, Loskutoff DJ, and Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem. 2005; 280:24792-24803.
105. Schiller HB, Szekeres A, Binder BR, Stockinger H, and Leksa V. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. Molecular biology of the cell. 2009; 20:745-756.
106. Xue W, Mizukami I, Todd RF, and Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997; 57:1682-1689.
107. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, and Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci US. 1993;90:5021-5025
108. Mohanam S, Chandrasekar N, Yanamandra N, Khawar S, Mirza F, Dinh DH, Olivero WC, and Rao JS. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene. 2002; 21:7824-7830.
109. Hu XW, Duan HF, Gao LH, Pan SY, Li YM, Xi Y, Zhao SR, Yin L, Li JF, Chen HP, and Wu CT. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol Ther. 2008; 7:651-659.
110. Burgle M, Koppitz M, Riemer C, Kessler H, Konig B, Weidle UH, Kellermann J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O, and Magdolen V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biological chemistry. 1997; 378:231-237.
111. Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Kruger A, and Magdolen V. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett . 2002;528:212-216.
112. Rabbani SA, and Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 2002; 62:2390-2397
113. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, and Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 2005; 65:7775-7781.
114. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, and Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007; 177:927-939
115. Mazar AP, Ahn RW, and O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011; 17:1970-1978.